Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies.

Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, Dang J, Yang H, Zhu S, Kohyama J, Kitabayashi I, Cavenee WK, Cloughesy TF, Furnari FB, Nakamura M, Toyama Y, Okano H, Mischel PS.

Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4339-44. doi: 10.1073/pnas.1217602110. Epub 2013 Feb 25.

PMID:
23440206
2.

Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.

Zhou W, Cheng L, Shi Y, Ke SQ, Huang Z, Fang X, Chu CW, Xie Q, Bian XW, Rich JN, Bao S.

Oncotarget. 2015 Nov 10;6(35):37300-15. doi: 10.18632/oncotarget.5836.

PMID:
26510911
3.

The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas.

Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, Assuncao A, Gu Y, Bonetti B, Mortensen DS, Xu S, Raymon HK, Cavenee WK, Furnari FB, James CD, Kroemer G, Heath JR, Hege K, Chopra R, Cloughesy TF, Mischel PS.

Clin Cancer Res. 2013 Oct 15;19(20):5722-32. doi: 10.1158/1078-0432.CCR-13-0527. Epub 2013 Sep 12.

PMID:
24030701
4.

SCP phosphatases suppress renal cell carcinoma by stabilizing PML and inhibiting mTOR/HIF signaling.

Lin YC, Lu LT, Chen HY, Duan X, Lin X, Feng XH, Tang MJ, Chen RH.

Cancer Res. 2014 Dec 1;74(23):6935-46. doi: 10.1158/0008-5472.CAN-14-1330. Epub 2014 Oct 7.

PMID:
25293974
5.

Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.

Zhang X, Yang XR, Sun C, Hu B, Sun YF, Huang XW, Wang Z, He YF, Zeng HY, Qiu SJ, Cao Y, Fan J, Zhou J.

Cancer Lett. 2015 Sep 28;366(1):112-22. doi: 10.1016/j.canlet.2015.06.014. Epub 2015 Jun 25.

PMID:
26118777
6.

The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1.

Mathieu MG, Miles AK, Ahmad M, Buczek ME, Pockley AG, Rees RC, Regad T.

Cell Death Dis. 2014 Feb 13;5:e1061. doi: 10.1038/cddis.2014.29.

PMID:
24525737
7.

Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma.

Zheng T, Yin D, Lu Z, Wang J, Li Y, Chen X, Liang Y, Song X, Qi S, Sun B, Xie C, Meng X, Pan S, Liu J, Jiang H, Liu L.

Mol Cancer. 2014 May 31;13:133. doi: 10.1186/1476-4598-13-133.

PMID:
24884809
8.

Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.

Isakson P, Bjørås M, Bøe SO, Simonsen A.

Blood. 2010 Sep 30;116(13):2324-31. doi: 10.1182/blood-2010-01-261040. Epub 2010 Jun 23.

PMID:
20574048
9.

Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.

Wang ZG, Rivi R, Delva L, König A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell RP Jr, Pandolfi PP.

Blood. 1998 Sep 1;92(5):1497-504.

PMID:
9716575
10.

PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR.

Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, Cordon-Cardo C, Simon MC, Rafii S, Pandolfi PP.

Nature. 2006 Aug 17;442(7104):779-85.

PMID:
16915281
11.

Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.

Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Nov 15;20(22):5756-67. doi: 10.1158/1078-0432.CCR-13-3389. Epub 2014 Oct 14.

PMID:
25316808
12.

Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384.

Zhu Y, Shah K.

Cancer Biol Ther. 2014 Jun 1;15(6):815-22. doi: 10.4161/cbt.28585. Epub 2014 Mar 21.

PMID:
24658109
13.

Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.

Ablain J, Rice K, Soilihi H, de Reynies A, Minucci S, de Thé H.

Nat Med. 2014 Feb;20(2):167-74. doi: 10.1038/nm.3441. Epub 2014 Jan 12.

PMID:
24412926
14.
15.

The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.

Lång E, Grudic A, Pankiv S, Bruserud O, Simonsen A, Bjerkvig R, Bjørås M, Bøe SO.

Blood. 2012 Jul 26;120(4):847-57. doi: 10.1182/blood-2011-10-388496. Epub 2012 Jun 12.

PMID:
22692509
16.

Compensatory glutamine metabolism promotes glioblastoma resistance to mTOR inhibitor treatment.

Tanaka K, Sasayama T, Irino Y, Takata K, Nagashima H, Satoh N, Kyotani K, Mizowaki T, Imahori T, Ejima Y, Masui K, Gini B, Yang H, Hosoda K, Sasaki R, Mischel PS, Kohmura E.

J Clin Invest. 2015 Apr;125(4):1591-602. doi: 10.1172/JCI78239. Epub 2015 Mar 23.

PMID:
25798620
17.

Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.

Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, Zhang QY, Yang HY, Huang QH, Zhou GB, Tong JH, Zhang Y, Wu JH, Hu HY, de Thé H, Chen SJ, Chen Z.

Science. 2010 Apr 9;328(5975):240-3. doi: 10.1126/science.1183424. Erratum in: Science. 2010 May 21;328(5981):974.

PMID:
20378816
18.

Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.

Percherancier Y, Germain-Desprez D, Galisson F, Mascle XH, Dianoux L, Estephan P, Chelbi-Alix MK, Aubry M.

J Biol Chem. 2009 Jun 12;284(24):16595-608. doi: 10.1074/jbc.M109.006387. Epub 2009 Apr 20.

PMID:
19380586
19.

Pml represses tumour progression through inhibition of mTOR.

Bernardi R, Papa A, Egia A, Coltella N, Teruya-Feldstein J, Signoretti S, Pandolfi PP.

EMBO Mol Med. 2011 May;3(5):249-57. doi: 10.1002/emmm.201100130. Epub 2011 Mar 8.

PMID:
21387562
20.

Regulatory effects of mammalian target of rapamycin-mediated signals in the generation of arsenic trioxide responses.

Altman JK, Yoon P, Katsoulidis E, Kroczynska B, Sassano A, Redig AJ, Glaser H, Jordan A, Tallman MS, Hay N, Platanias LC.

J Biol Chem. 2008 Jan 25;283(4):1992-2001. Epub 2007 Nov 29.

PMID:
18048359

Supplemental Content

Support Center